IVF Tedavi Öncesi Androjenlerin Yeri
Özet
Referanslar
Ben-Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG. J In Vitro Fert Embryo Transf. 1991;8(1):33
Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. Journal of Assisted Reproduction and Genetics 2007;24(12):629–34.
Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction 2000;15(10):2129-32.
Gleicher N, Kim A, Weghofer A, Shohat-Ta A, Lazzaroni E, Lee HJ, et al. Starting and resulting testosterone levels aHer androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). Journal of Assisted Reproduction and Genetics 2013;30(1):49-62.
Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Human Reproduction 2006;21(7):1884-93.
Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. Journal of Clinical Endocrinology & Metabolism 1968;28(3):355-8.
Weil S, Vendola K, Zhou J, Bondy CA. Androgen and folliclestimulating hormone interactions in primate ovarian follicle development. Journal of Clinical Endocrinology and Metabolism 1999;84(8):2951-6.
Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertility and Sterility 2005;84(1):82-7.
Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Møllgård K, Wreford Andersen E, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction 2011;17(1):63-70.
Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Molecular Endocrinology 2010;24(7):1393–403.
Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility and Sterility 2001;76(2):241-8.
Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Current Opinion in Obstetrics and Gynaecology 2009;21(4):306-8.
Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve?. Journal of Assisted Reproduction and Genetics 2013;30(9):1239–44
Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015;11:Cd009749. https://doi. org/10.1002/14651858.CD009749.pub2
Zhu et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis Reproductive Biology and Endocrinology (2023) 21:64
Referanslar
Ben-Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG. J In Vitro Fert Embryo Transf. 1991;8(1):33
Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. Journal of Assisted Reproduction and Genetics 2007;24(12):629–34.
Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction 2000;15(10):2129-32.
Gleicher N, Kim A, Weghofer A, Shohat-Ta A, Lazzaroni E, Lee HJ, et al. Starting and resulting testosterone levels aHer androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). Journal of Assisted Reproduction and Genetics 2013;30(1):49-62.
Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Human Reproduction 2006;21(7):1884-93.
Ryan KJ, Petro Z, Kaiser J. Steroid formation by isolated and recombined ovarian granulosa and thecal cells. Journal of Clinical Endocrinology & Metabolism 1968;28(3):355-8.
Weil S, Vendola K, Zhou J, Bondy CA. Androgen and folliclestimulating hormone interactions in primate ovarian follicle development. Journal of Clinical Endocrinology and Metabolism 1999;84(8):2951-6.
Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertility and Sterility 2005;84(1):82-7.
Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Møllgård K, Wreford Andersen E, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction 2011;17(1):63-70.
Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Molecular Endocrinology 2010;24(7):1393–403.
Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility and Sterility 2001;76(2):241-8.
Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Current Opinion in Obstetrics and Gynaecology 2009;21(4):306-8.
Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve?. Journal of Assisted Reproduction and Genetics 2013;30(9):1239–44
Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015;11:Cd009749. https://doi. org/10.1002/14651858.CD009749.pub2
Zhu et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis Reproductive Biology and Endocrinology (2023) 21:64
